Jan Misik
Overview
Explore the profile of Jan Misik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herman D, Dlabkova A, Cechova L, Vanova N, Misik J, Jun D, et al.
Drug Test Anal
. 2019 Dec;
12(4):431-438.
PMID: 31785126
Agent BZ (3-quinuclidinyl benzilate) is a centrally acting synthetic anticholinergic agent, considered as a potential military incapacitating chemical warfare agent. Despite its significance as a model compound in pharmacological research...
2.
Hepnarova V, Muckova L, Ring A, Pejchal J, Herman D, Misik J, et al.
Toxicol Appl Pharmacol
. 2019 Oct;
383:114776.
PMID: 31629733
The major function of compounds with an oxime moiety attached to a quarternary nitrogen pyridinium ring is to reactivate acetylcholinesterase inhibited by organophosphorus agent (OP). However, other oxime mechanisms (e.g....
3.
Valis M, Herman D, Vanova N, Masopust J, Vysata O, Hort J, et al.
Front Pharmacol
. 2019 Sep;
10:943.
PMID: 31555132
Memantine is a noncompetitive -methyl-d-aspartate (NMDA) receptor antagonist utilized as a palliative cure for Alzheimer's disease. This is the second study examining the memantine concentrations in cerebrospinal fluid. The previously...
4.
Zdarova Karasova J, Soukup O, Korabecny J, Hroch M, Krejciova M, Hrabinova M, et al.
Drug Chem Toxicol
. 2019 Jul;
44(2):207-214.
PMID: 31257938
The search for tacrine derivatives, as potential Alzheimer´s disease treatment, is still being at the forefront of scientific efforts. 7-MEOTA was found to be a potent, centrally active acetylcholinesterase inhibitor...
5.
Chalupova K, Korabecny J, Bartolini M, Monti B, Lamba D, Caliandro R, et al.
Eur J Med Chem
. 2019 Mar;
168:491-514.
PMID: 30851693
A combination of tacrine and tryptophan led to the development of a new family of heterodimers as multi-target agents with potential to treat Alzheimer's disease. Based on the in vitro...
6.
Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, et al.
Med Res Rev
. 2018 Nov;
39(3):961-975.
PMID: 30426515
Narcolepsy is a rare, chronic neurological disease characterized by excessive daytime sleepiness, cataplexy, vivid hallucinations, and sleep paralysis. Narcolepsy occurs in approximately 1 of 3000 people, affecting mainly adolescents aged...
7.
Caisberger F, Pejchal J, Misik J, Kassa J, Valis M, Kuca K
BMC Pharmacol Toxicol
. 2018 Jun;
19(1):35.
PMID: 29954446
Background: The aim of our study was to compare the ability of two combinations of oximes (HI-6 + trimedoxime and HI-6 + K203) with atropine to counteract acute sarin-induced brain...
8.
Misik J, Nepovimova E, Pejchal J, Kassa J, Korabecny J, Soukup O
Curr Alzheimer Res
. 2017 Dec;
15(6):552-560.
PMID: 29231138
Background: 6-chlorotacrine is a cholinesterase inhibitor showing good inhibitory potential, even better than parent compound tacrine, in vitro. Despite tacrine scaffold is broadly used for design and synthesis of novel...
9.
Mezeiova E, Korabecny J, Sepsova V, Hrabinova M, Jost P, Muckova L, et al.
Molecules
. 2017 Aug;
22(8).
PMID: 28788095
Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer's disease (AD), was withdrawn from the market due to its side...
10.
Pavlikova R, Misik J, Cabal J, Marek J, Kuca K
Cutan Ocul Toxicol
. 2017 Jul;
37(1):77-83.
PMID: 28724312
The aim of this study was to determine optimal conditions for in vitro skin decontamination using water and detergents as decontamination agents and to test the cleansing efficiency of selected...